Leadership and Board of Directors
Thierry Dervieux, Ph.D. has served as our Chief Scientific Officer and Medical Laboratory Director since October 2010. Dr. Dervieux has nearly 20 years of experience with the development of drug monitoring and molecular diagnostic assays in partnership with academia and diagnostic industry. Prior to joining Exagen, Dr. Dervieux was Vice President of Research and Development with Cypress Bioscience, Inc., a pharmaceutical company with a focus on drugs to treat central nervous system disorders, where he developed our current portfolio in the rheumatology space from 2008 to October 2010. He previously served as Senior Director Research and Development with Proprius Pharmaceuticals, Inc., a specialty pharmaceutical and personalized medicine company focused in rheumatology and pain management, until its acquisition by Cypress Bioscience. Prior to that, he served as Principal Scientist and Director of Research and Development at Prometheus Laboratories. Dr. Dervieux is board certified by the American Board of Clinical Chemistry and holds certificates of qualification as medical laboratory director in the categories of cellular immunology, clinical chemistry, drug monitoring, genetic testing and diagnostic immunology. Dr. Dervieux holds Pharm.D. and Ph.D. degrees from Claude Bernard University in Lyon, France, an inter-university diploma in biostatistics from the University of Pierre et Marie Curie in Paris, France, and trained at St. Jude Children's Research Hospital in Memphis, Tennessee.
Brian McEvilly has served as our Vice President of Marketing since February 2016. Brian joined us with 20 years of medical sales & marketing experience. Prior to joining Exagen Brian held leadership roles at WomanCare Global as their Vice President of Marketing and at Inova Diagnostics where he spent 5 years as the Director of Global Marketing. He also played an important role in the initial launch of the AVISE brand as the Director of Personalized Medicine at Cypress Bioscience from 2008-2010. The personalized medicine offering at Cypress was later acquired by Exagen allowing Mr. McEvilly to quickly make meaningful contributions to the continued growth of this familiar franchise. Brian’s career in medical marketing began in 1998 when he excelled in various Sales and Marketing roles at Sunrise Medical, Quidel and later Gen-Probe (Hologic). Mr. McEvilly holds a Bachelor of Business Administration from the University of San Diego and earned his MBA degree from University of California, Irvine where he graduated with honors.
President & CEO
Fortunato Ron Rocca has served as our President and Chief Executive Officer and as a member of our board of directors since December 2011. From 2005 to October 2011,...
Dr. Thierry Dervieux
Chief Scientific Officer, Medical Director, New York
Thierry Dervieux, Ph.D. has served as our Chief Scientific Officer and Medical Laboratory Director since October 2010. Dr. Dervieux has nearly 20 years of experience...
Chief Financial Officer
Kamal Adawi has served as our Chief Financial Officer since June 2017. Kamal previously held the positions of Chief Financial Officer, Corporate Secretary and...
Arthur Weinstein, M.D.
Chief Medical Officer
Arthur Weinstein, M.D. has served as our Chief Medical Officer since October 2017 and has been a member of our board of directors since December 2013. Dr. Weinstein...
Senior Vice President Laboratory Operations
Claudia Ibarra has served as our Senior Vice President, Laboratory Operations since January 2017, after being our Vice President, Laboratory Operations from 2014. She...
Vice President of Finance
Mark Hazeltine has served as our Vice President of Finance since June 2017. Mr. Hazeltine served as Exagen’s Sr. Director of Financial Planning and Analysis...
Vice President, Information Services
Brian Littlefield has served as our Vice President, Information Services since April 2014. Prior to joining Exagen, Mr. Littlefield served as the Senior Director,...
Vice President of Marketing
Brian McEvilly has served as our Vice President of Marketing since February 2016. Brian joined us with nearly 20 years of medical marketing experience including his...
Tami Powell (York)
Vice President, Corporate Payer and Reimbursement Strategy
Tami Powell has served as our Vice President of Corporate Payer and Reimbursement Strategy since September 2017, after being our Senior Director, Corporate Payer...
Vice President, Sales & Managed Markets
John Wegener has served as our Vice President, Sales and Managed Markets since November 2013. Prior to joining Exagen, Mr. Wegener served in various capacities with...
Board of Directors
Jim Tullis founded Tullis Health Investors ("THI" or "Tullis-Dickerson & Co., Inc.") in 1986 and has a career of over 40 years in health care investing. Prior to establishing Tullis Health Investors, Jim was a Senior Vice President of E.F. Hutton & Co. (1983-1986) and a Principal at Morgan Stanley & Co. (1974-1983), where he led health care investment research and, later, healthcare investment banking. During his tenure at Morgan Stanley, he received recognition 14 times on the Institutional Investor All-Star list of Wall Street's top securities analysts and listing as a top home run hitter. He was twice named #1 Drug Analyst and was featured on the Wall Street Week television program. From 1972-1974, Jim was Vice President of Putnam Funds researching health care industry equities. Under Jim's direction, THI has managed several venture capital funds investing into the health care industry. Winning portfolio companies of those funds include Adams Respiratory and Sirion (with innovative concepts in pharmaceuticals); Synageva and BioRexis (biotechnology); Atritech and Vidacare (medical devices); PSS World Medical and Impulse Monitoring (medical services); and Intelliclaim and QuadraMed (health care information technology). Jim is a graduate of Stanford University and earned an MBA from Harvard Business School. He currently sits on the Boards of the Lord Abbett family of mutual funds, Crane Corporation (NYSE: CR), SupplyPro, Inc., Exagen Inc., and electroCore, LLC.
Tina S. Nova, Ph.D. has extensive experience growing dynamic commercial organizations in new markets within the molecular diagnostics field. Since August 2018, she has served as president and chief executive officer of Decipher Biosciences, Inc., a diagnostics company focused on urologic cancers. Previously Dr. Nova was president and chief executive officer of Molecular Stethoscope, Inc., and served as senior vice president and general manager of Illumina’s oncology business unit. Dr. Nova was a co-founder of Genoptix, a medical laboratory diagnostics company, and served as its president and chief executive officer from 2000 to 2014. Genoptix was acquired by Novartis AG in 2011. Dr. Nova was co-founder of Nanogen, a provider of molecular diagnostic tests, and served as its chief operating officer and president from 1994 to 2000. She previously served as chief operating officer of Selective Genetics, and held various positions with Ligand Pharmaceuticals and Hybritech. Dr. Nova serves as the chair of the board of directors for Arena Pharmaceuticals and as a member of the board of directors of Veracyte, a diagnostics company. Dr. Nova received a bachelor’s degree in biological sciences from the University of California, Irvine, and a doctorate in biochemistry from the University of California, Riverside.
Bruce Robertson, Ph.D. is a Managing Director of H.I.G. BioHealth Partners, the healthcare affiliate of H.I.G. Capital, a private equity firm with over $31 billion under management. Dr. Robertson has been active in the life sciences sector for more than 30 years. Prior to joining H.I.G., he served most recently as Managing Director at Toucan Capital, a venture capital fund focusing on healthcare investments. Prior to his private equity career, Dr. Robertson was Director of Business Development at IGEN International, where he was responsible for formulating and implementing IGEN's partnering and M&A strategies. Dr. Robertson started his career as a Research Manager at W.R. Grace & Co., focusing on medical devices. Dr. Robertson currently serves on the boards of Apollo Endosurgery, RxSight, CardioFocus, Clarus Therapeutics, Iconic Therapeutics, and Intact Vascular. Dr. Robertson holds a BSE in Chemical Engineering and BA in Mathematics from the University of Pennsylvania, a Ph.D. in Chemical Engineering from the University of Delaware, and an MBA with High Distinction from Harvard Business School. Ron Rocca, CEO at Exagen, shared “we are delighted to have such talented and experienced individuals join our team bringing a critical range of expertise. With the deep understanding of the payer perspective from Chet Burrell, the track record of successful public companies of Tina Nova, and the deep understanding of the broader healthcare space from Bruce Robertson, we are positioning Exagen for success in the next phase of our growth.” The three new members join the current Board of Directors which includes James Tullis, Beto Pallares, Brian Birk, Jeff Elliott, and Ron Rocca.